Lymphoglobuline

Also used as a comparator or background therapy in 2 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT01145976 Background	Mar 2010 → Feb 2015	aplastic anemia	Cooperative Study Group A for Hematology	Unknown	No outcome recorded
Phase 3	NCT00774527 Comparator	Mar 2003 → Feb 2010	bone marrow failure syndrome	Cooperative Study Group A for Hematology	Completed	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Lymphoglobuline	“Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2.” NCT01145976 ↗ 1 “Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2.” NCT00774527 ↗
Route	Intravenous	“Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2.” NCT00774527 ↗